Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis
Arthritis Care & Research · 15.04.2009 · 61 (4) · 419-424
DOI: 10.1002/art.24390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 30.03.2009. Verfasst von Francisco Javier López-Longo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Universitario Gregorio Marañón, Madrid, Spain. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease that may not always be related to the presence of traditional cardiovascular risk factors. The aim of this study was to determine if anti–cyclic citrullinated peptide (anti‐CCP) antibodies are associated with cardiovascular disease in patients with RA.
Methods
Anti‐CCP antibodies were determined by enzyme‐linked immunosorbent assay in the earliest serum sample available from 937 patients with a diagnosis of RA. We studied the relationship between anti‐CCP antibodies with traditional cardiovascular risk factors and cardiovascular events.
Results
We found positive anti‐CCP antibodies (>25 units/ml) in 672 patients (71.7%). There was no association between the anti‐CCP antibodies and cardiovascular risk factors such as smoking, hypertension, dyslipidemia, being overweight, or diabetes mellitus. However, patients who had positive anti‐CCP antibodies experienced more frequent ischemic heart disease (6.5% versus 2.6%; odds ratio [OR] 2.58, 95% confidence interval [95% CI] 1.17–5.65) and had higher mortality rates (11.2% versus 6.8%; OR 1.72, 95% CI 1.01–2.91). Similar results were obtained when we considered anti‐CCP titers 20‐fold higher (>500 units/ml). Multivariable analysis showed that ischemic heart disease is independently associated with positive anti‐CCP antibodies (OR 2.8, 95% CI 1.19–6.56; P = 0.009).
Conclusion
Anti‐CCP antibodies in patients with RA are independently associated with the development of ischemic heart disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Zitieren
APA
López-Longo, F. J., Oliver-Miñarro, D., de la Torre, I., González-Díaz de Rábago, E., Sánchez-Ramón, S., Rodríguez-Mahou, M., Paravisini, A., Monteagudo, I., González, C. M., García-Castro, M., Casas, M. D., & Carreño, L. (2009). Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Care & Research, 61(4), 419-424. https://doi.org/10.1002/art.24390
Vancouver
López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Care & Research. 2009;61(4):419-424. doi:10.1002/art.24390
BibTeX
@article{LpezLongo2009,
author = {López-Longo, Francisco Javier and Oliver-Miñarro, Desamparados and de la Torre, Inmaculada and González-Díaz de Rábago, Eugenia and Sánchez-Ramón, Silvia and Rodríguez-Mahou, Margarita and Paravisini, Alexandra and Monteagudo, Indalecio and González, Carlos-Manuel and García-Castro, Marta and Casas, María Dolores and Carreño, Luis},
title = {Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis},
journal = {Arthritis Care & Research},
year = {2009},
volume = {61},
number = {4},
pages = {419--424},
doi = {10.1002/art.24390}
}
EUVIMED